Bicara Therapeutics Inc(BCAX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 7:42 PM ET (Korea 10/31 08:42)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.09 | Insider Own | 33.86% | Shs Outstand | 65.9M | Perf Week | -46.51% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | -5.75% | Insider Trans | -0.72% | Shs Float | 43.8M | Perf Month | -49.84% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -0.82 | Inst Own | 77.41% | Short Float | 23.53% | Perf Quarter | -64.53% |
| Income | -0.19B | P/S | - | EPS this Y | -35.78% | Inst Trans | -2.62% | Short Ratio | 10.61 | Perf Half Y | -57.87% |
| Sales | 0.00B | P/B | 1.28 | EPS next 5Y | -10.86% | ROA | -38.38% | Short Interest | 10.30M | Perf YTD | -45.75% |
| Book/sh | 7.11 | P/C | 1.21 | EPS past 3/5Y | -53.65% - | ROE | -41.01% | 52W High | -70.54% ($30.99) | Perf Year | -44.53% |
| Cash/sh | 7.51 | P/FCF | - | Sales past 3/5Y | - | ROIC | -39.54% | 52W Low | 2.58% ($8.90) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -63.7% | Gross Margin | - | Volatility(W/M) | 26.41% 11% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.59 | EPS Q/Q | -62.5% | Profit Margin | - | RSI (14) | 17.49 | Recom | 1.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.59 | Sales Q/Q | - | SMA20 | -43.44% ($16.14) | Beta | -0.64 | Target Price | $33.18 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/11 | SMA50 | -53.75% ($19.74) | Rel Volume | 4.32 | Prev Close | $9.73 |
| Employees | 103 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -0.02% - | SMA200 | -56.95% ($21.21) | Avg Volume(3M) | 0.97M | Price | $9.13 |
| IPO | 2024/9/13 | Option/Short | Yes/Yes | Trades | 18061 | Volume | 4,195,752 | Change | -6.17% |
🧬 Bicara Therapeutics is a US-based clinical-stage biotech company developing dual-function antibody-based oncology drugs. Its lead candidate, ficerafusp alfa, is a first-in-class molecule that binds both the epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-β) on a single antibody. The company is running clinical trials primarily in head and neck squamous cell carcinoma. Bicara's approach aims to remodel the tumor microenvironment to enhance the response to immuno-oncology therapies.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded more than usual. That is 432% of its average volume.
BCAX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -35.8% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #198 of 597 in the industry
Based on market cap of $604M.
OLMA#196 Olema Pharmaceuticals Inc $612M PER - 
ZVRA#197 Zevra Therapeutics Inc $610M PER 11.1 BCAX#198 Bicara Therapeutics Inc $604M PER - 
NVCT#199 Nuvectis Pharma Inc $603M PER - 
DBVT#200 DBV Technologies ADR $596M PER - 
FAQ
What kind of company is BCAX?
BCAX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BCAX?
The market cap of BCAX is approximately $604M, ranking 2,992 within its sector.
What is the 52-week high and low for BCAX?
BCAX has recorded a 52-week high of $30.99 and a low of $8.90.
